1
TITLE: Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years
AUTHORS: Jiwon Oh; Anat Achiron; Elisabeth G Celius; Christina Chambers; Joy Derwenskus; Virginia Devonshire; Kerstin Hellwig; George J Hutton; Pamela McCombe; Marie Moore; David Rog; Jean Raphael Schneider; Renata Faria Simm; Livia Sousa; Stephen G Vincent; Luke K Chung; Nadia Daizadeh; Colin Mitchell; Alastair A S Compston;
PUBLISHED: 2020, SOURCE: MULTIPLE SCLEROSIS AND RELATED DISORDERS, VOLUME: 43
INDEXED IN: Scopus WOS
2
TITLE: Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
AUTHORS: Tjalf Ziemssen; Ann D Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M J Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A Singer;
PUBLISHED: 2020, SOURCE: CNS DRUGS, VOLUME: 34, ISSUE: 9
INDEXED IN: Scopus WOS